Most laboratories compete on price, turnaround, and panel size. The laboratories that win compete on what providers actually do with the result. AICC adds pathologist-led consultation to every complex molecular case, returned under your brand, integrated into your existing workflow.
A list of pathogens and resistance markers is data. A pathologist-signed recommendation for the narrowest effective therapy is a clinical decision aid. Your providers stop puzzling over the result and start treating the patient.
Algorithm-only competitors cannot match expert interpretation. When two labs return the same organism list and one returns a signed consultation with treatment guidance, providers remember which one supported them. Loyalty follows.
Every consultation is reviewed and signed by a board-certified pathologist. That signature is what makes the report clinically defensible and professionally credible. Algorithm-only services cannot match it.
When the consultation is in the report, providers do not need to call to ask what an unfamiliar resistance gene implies. Your client services team handles the calls that actually require them.
Providers stay with the laboratory that supports them. The consultation is not a marketing claim. It is a daily piece of evidence that your laboratory delivers more than a result.
Every consultation recommends the narrowest effective therapy. Over time, your laboratory becomes part of the antimicrobial stewardship effort, not a contributor to broad-spectrum overuse.
New entrants compete on price and panel size. AICC consultation is the difference between selling a commodity test and selling a clinical service.
AICC integrates with your existing workflow. Your operations team is not asked to learn a new system or run a parallel process. Results route to our pathology team automatically the moment they are released, and signed consultations return into your existing reporting flow.
Detailed integration discussion happens after a discovery call so we can match the approach to your specific systems.
The signing pathologist's name and credentials appear on the consultation. The laboratory's brand and logo appear on the larger report. Providers see one unified document delivered by your laboratory, with the pathologist's signature providing the clinical authority behind the recommendation.
AICC is currently focused on complex molecular diagnostics, particularly multiplex pathogen panels with resistance gene detection. The consultation model extends naturally to adjacent test categories where structured laboratory data benefits from specialist interpretation.
If your laboratory runs a test category not listed publicly, raise it on the discovery call. The framework is broader than what we describe externally.
Yes. The laboratory's underlying test result is unchanged by the consultation. AICC's pathologist reviews the released result and provides a separate professional consultation report on the clinical implications, distinct from the laboratory's analytical interpretation.
A board-certified pathologist is available to discuss the case directly. Not a call center. Not a chatbot. Complex cases deserve real conversations, and providers remember which laboratories make those conversations possible.
The first step is a 30 minute discovery call. We discuss your laboratory's existing operation, the test categories of interest, and where the consultation would add value. From there, the engagement proceeds at a pace that fits your operational and compliance timeline.
There is no obligation to commit on the first call. The goal is to determine fit.